FDA reviews continue for now

Share this article:

Banked user fees are keeping the FDA review process humming for now, reports MedPage Today, which notes that the agency approved the prescription hot flashes medication Duavee Thursday and plans to hold its advisory committee meeting for Medtronic devices this week. This in addition to green-lighting an IV nutritional treatment called Clinolipid on Thursday.

The omega-three/omega-six fatty acid blend was granted priority review to alleviate a drug shortage. MedPage Today notes that although user fees fund the regulator's review processes, they only cover around two-thirds of the cost, putting future reviews in limbo under the shutdown. As noted last week, more than half of the non-furloughed FDA employees are funded by user fees, but only 55% of the agency's staff is allowed to work until the shutdown is resolved.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.